These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3171626)

  • 1. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update.
    Logothetis CJ; Johnson DE; Chong C; Dexeus FH; Sella A; Ogden S; Smith T; Swanson DA; Babaian RJ; Wishnow KI
    J Clin Oncol; 1988 Oct; 6(10):1590-6. PubMed ID: 3171626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy of bladder cancer: a preliminary report.
    Logothetis CJ; Johnson DE; Chong C; Dexeus FH; Ogden S; von Eschenbach A; Ayala A
    J Urol; 1988 Jun; 139(6):1207-11. PubMed ID: 3373589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative and postoperative adjuvant chemotherapy using CISCA (cyclophosphamide, doxorubicin, and cisplatin) in the treatment of invasive transitional-cell carcinoma of the bladder.
    Lynch DF
    Urol Clin North Am; 1991 Aug; 18(3):543-6. PubMed ID: 1877118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preliminary results of prophylactic adjuvant chemotherapy with CISCA in bladder tumors].
    Bittard H
    J Urol (Paris); 1988; 94(7):345-7. PubMed ID: 2464650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors.
    Logothetis CJ; Samuels ML; Selig DE; Wallace S; Johnson DE
    Cancer Treat Rep; 1985 Jan; 69(1):33-8. PubMed ID: 2981619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement.
    Stöckle M; Wellek S; Meyenburg W; Voges GE; Fischer U; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    Urology; 1996 Dec; 48(6):868-75. PubMed ID: 8973669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-cystectomy chemotherapy with sequentially administered cisplatin, cyclophosphamide and adriamycin in invasive transitional cell carcinoma of the bladder (preliminary report).
    Guazzieri S; Sperandio P; Fandella A; Garbeglio A; Pegoraro V; Chiarion V; Fiorentino M; Pagano F
    Prog Clin Biol Res; 1988; 260():599-602. PubMed ID: 3362909
    [No Abstract]   [Full Text] [Related]  

  • 13. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.
    Logothetis CJ; Dexeus FH; Finn L; Sella A; Amato RJ; Ayala AG; Kilbourn RG
    J Clin Oncol; 1990 Jun; 8(6):1050-5. PubMed ID: 2189954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M-VAC versus CisCA--chemotherapy in the treatment of advanced bladder cancer.
    Heimbach D; Wirth M; Frohmüller H
    Urol Int; 1992; 48(2):157-61. PubMed ID: 1585511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of adjuvant chemotherapy after radical cystectomy for deeply invasive bladder cancer.
    Skinner DG; Daniels JR; Lieskovsky G
    Urology; 1984 Jul; 24(1):46-52. PubMed ID: 6539997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nordic prospective trials of radical cystectomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer Study Group.
    Hellsten S; Rintala E; Wahlqvist R; Malmström PU
    Eur Urol; 1998; 33 Suppl 4():35-8. PubMed ID: 9615209
    [No Abstract]   [Full Text] [Related]  

  • 17. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
    Park J; Park S; Song C; Doo C; Cho YM; Ahn H; Kim CS
    Urology; 2007 Aug; 70(2):257-62. PubMed ID: 17826485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Polychemotherapy treatment with cisplatin, adriamycin, 5-fluorouracil (FAP) and cisplatin, adriamycin and cyclophosphamide (CISCA) in advanced transitional carcinoma of the bladder].
    Sánchez Romero JA; Ramírez Ruiz F; Romero Fernández L; Pastor Gaitán P; Murillo Capitán E
    Actas Urol Esp; 1989; 13(4):240-2. PubMed ID: 2678934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer.
    Hrushesky WJ; Roemeling RV; Wood PA; Langevin TR; Lange P; Fraley E
    Cancer Treat Rep; 1987 Oct; 71(10):915-9. PubMed ID: 3652055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
    Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.